BioCentury
ARTICLE | Company News

Kemin, Meiji Seika Kaisha deal

June 15, 2009 7:00 AM UTC

Kemin's Amalyte Pharmaceuticals LLC subsidiary received an exclusive license to develop and commercialize ME3301/ AM3301 and its follow-on compounds outside Japan and several Asian countries, where M...